Inovio Pharmaceuticals (INO) Return on Capital Employed (2011 - 2026)
Inovio Pharmaceuticals (INO) posted Return on Capital Employed of 347.1% for Q1 2026, down 12.65% sequentially from 308.11% in Q4 2025, and down 20176.0% YoY from N/an in Q1 2025.
Inovio Pharmaceuticals (INO) Return on Capital Employed (2011 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Return on Capital Employed for 16 years, with the latest figure at 347.1% in Q1 2026.
- Quarterly Return on Capital Employed fell 20176.0% year-over-year to 347.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 347.1% (down 20176.0% YoY) and the FY2025 annual result came in at 173.35%, down 6806.0% from the prior year.
- Return on Capital Employed declined to 347.1% in Q1 2026 per INO's latest filing, from 308.11% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 8875.51% in Q3 2025 and troughed at 347.1% in Q1 2026.
- A 5-year average of 388.4% and a median of 103.82% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed soared 899872 bps in 2025, then sank 20176 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 97.88% in 2022, then fell by 5 bps to 103.22% in 2023, then plunged by 46 bps to 150.26% in 2024, then tumbled by 105 bps to 308.11% in 2025, then dropped by 13 bps to 347.1% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 347.1%, 308.11%, and 8875.51% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | -819.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -819.81% |
| Mar 31, 2026 | -347.10% |
| Dec 31, 2025 | -308.11% |
| Sep 30, 2025 | 8,875.51% |
| Jun 30, 2025 | -208.15% |
| Mar 31, 2025 | -145.34% |
| Dec 31, 2024 | -150.26% |
| Sep 30, 2024 | -123.21% |
| Jun 30, 2024 | -121.49% |
| Mar 31, 2024 | -103.82% |
| Dec 31, 2023 | -103.22% |
| Sep 30, 2023 | -101.85% |
| Jun 30, 2023 | -87.27% |
| Mar 31, 2023 | -95.00% |
| Dec 31, 2022 | -97.88% |
| Sep 30, 2022 | -95.88% |
| Jun 30, 2022 | -106.20% |
| Mar 31, 2022 | -77.89% |
| Dec 31, 2021 | -66.92% |
| Sep 30, 2021 | -43.92% |